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CD147 promotes cell motility 
via upregulation of p190-B RhoGAP 
in hepatocellular carcinoma
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Abstract 
Background: The acquisition of inappropriate migratory feature is crucial for tumor metastasis. Rho‑family GTPases 
including RhoA are molecular switches that play critical roles in regulating cell movement. We investigated the 
molecular mechanism underlying CD147 induced RhoA deactivation in hepatocellular carcinoma (HCC) cells.
Methods: Wound‑healing assay was performed to study the cell motility. Analysis of RhoA activation in living cells 
was conducted using RhoA biosensor. Changes in the expression of certain genes were determined by quantitative 
real‑time PCR. The expression of proteins was evaluated by Western blot. Cytoskeleton reorganization and focal adhe‑
sion formation were observed by immunofluorescence staining. Further investigation on the correlation between 
CD147 and p190‑B RhoGAP (p190‑B) in HCC tissues was performed by immunological histological chemistry analysis.
Results: CD147 promoted cell movement and suppressed RhoA activation. p190‑B, a negative regulator of RhoA 
activity, was upregulated by CD147 at both mRNA and protein levels. This regulatory relationship was further con‑
firmed by analyzing the expression pattern of CD147 and p190‑B in human HCC tissues. Silencing of p190‑B caused 
the increased formation of stress fiber and focal adhesion and blunted the impact of CD147 overexpression on cell 
movement, indicating that the regulatory effect of CD147 on cell movement is mediated, at least partially, by p190‑B.
Conclusions: These findings indicated that p190‑B, a negative regulator of RhoA, is positively regulated by CD147 
and contributes to the regulation of cell movement in HCC. CD147 plays critical roles in the motility of cancer cells 
and may be therefore a valuable drug target for anti‑cancer therapy.
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Background
The majority of deaths associated with cancer are due to 
the metastasis of the original tumor cells [1]. The acqui-
sition of inappropriate migratory and invasive character-
istics is a common feature of all metastatic cancer cells. 
Rho family GTPases are intracellular signaling molecules 
that play critical roles in regulating cytoskeleton reor-
ganization and cell movement. The activities of most Rho 
family members including RhoA depend on a delicate 
balance between the GTP-bound, active state and the 
GDP-bound, inactive state. The cycling between these 
two states is positively controlled by guanine exchange 
factors (GEFs), and negatively controlled by GTPase-acti-
vating proteins (GAPs) [2]. In the activated form, they are 
competent in binding to a large number of effector pro-
teins, which leads to the activation of myriad numerous 
downstream signals. >80 RhoGEFs and >70 RhoGAPs 
have been discovered to regulate the activities of RhoGT-
Pases in mammals [3, 4]. The overabundance of RhoGEFs 
and RhoGTPases versus Rho GTPases substrates allows 
the regulators to function in a tissue/cell type-specific 
manner [5].
CD147 also known as extracellular matrix metallopro-
teinase inducer (EMMPRIN), is a type I transmembrane 
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glycoprotein. Previous studies showed that CD147 plays 
important roles in cellular processes of HCC progres-
sion, including adhesion [6], migration [7–9], invasion 
and metastasis [10]. Of note, CD147 interacts directly 
with annexin A2 and suppresses RhoA activity [7]. Also, 
CD147 enhances Src activity and promotes mesen-
chymal-type cell movement by up-regulating RacGEF 
DOCK8 [8], suggesting that CD147 may regulate cell 
motility via downregulation of RhoA and upregulation of 
Rac1, however, the underlying mechanisms are far from 
clear.
p190-B RhoGAP (p190-B) is a 190  kDa multidomain 
protein. The N-terminal domain of p190-B contains 
several motifs characteristic of a GTPase domain, while 
its C terminus contains a Rho GAP domain. p190-B is 
among the most important regulators of RhoA and the 
actin cytoskeleton. Mice lacking p190-B display defects 
in cell size, thymus and lung during fetal development. 
Also, p190-B loss in embryonic mesenchymal/fibroblasts 
leads to an imbalance in adipogenesis/myogenesis cell 
fate determination [11–13]. Loss of p190-B enhances 
hematopoietic stem cell (HSC) self-renewal ability [14] 
and p190-B is critical for the constitution of a functional 
mesenchymal-derived hematopoietic niche [15]. In cells, 
p190-B co-localizes with the α5β1 integrin receptor for 
fibronectin and is thought to be a negative regulator of 
RhoA activity [16, 17]. The junctional localization of 
p190-B can be inhibited by centralspindlin, leading to 
increased RhoA activity during cytokinesis in interphase 
cells at the zonula adherens [18]. All these results suggest 
that p190-B functions mainly via regulating RhoA activ-
ity. We hypothesized that if p190-B is critical for promot-
ing RhoA deactivation it might also play an important 
role during cancer cell movement in HCC.
In this study, we provide evidence that CD147 pro-
motes cell movement while inhibiting RhoA activity. 
CD147 enhances p190-B expression at both mRNA and 
protein levels and increased p190-B results in reduced 




Human SMMC-7721 hepatoma cell line was obtained 
from Chinese Academy of Medical Sciences. Huh-7 cells 
were obtained from the Japanese Collection of Research 
Bioresources. HepG2 cells were obtained from the Amer-
ican Type Culture Collection. All cell lines were routinely 
cultured using standard protocols. Transient transfection 
of plasmids was performed using Lipofectamine 2000 
(Life Technologies, US) according to the manufacturer’s 
protocol.
Tissue specimens and immunological histological 
chemistry (IHC) analysis
Forty-seven tissue specimens of HCC were collected 
from the Department of Hepatobiliary & Pancreas Sur-
gery, Xijing Hospital, which is affiliated with the Fourth 
Military Medical University (FMMU) from 2008 to 2009 
and were histological confirmed by staining with hema-
toxylin and eosin (H and E). All individuals provided 
written informed consent, and the study was approved by 
the hospital Ethics Committee. For IHC analysis, sections 
were incubated with primary antibodies and developed 
with the Histostain®-Plus Kit (Invitrogen, Carlsbad, CA). 
The expression level was independently evaluated by 
two senior pathologists according to the proportion and 
intensity of positive cells. The following criteria was used 
to score each specimen: 0 (no staining), 1 (any percent-
age with weak intensity or <30 % with strong intensity), 2 
(>30 % with strong intensity).
Antibodies, plasmids and biosensor
CD147-specific antibody HAb18 was produced by our 
lab; α-tubulin antibody (sc-8035) was purchased from 
Santa Cruz; p190-A antibody (2513) was obtained from 
Cell Signaling Technology; p190-B antibody (611612) and 
paxillin antibody (610620) were obtained from BD bio-
sciences; Alexa 594-conjugated goat anti-mouse IgG and 
Alexa Fluor 488 phalloidin were purchased from Invitro-
gen. A siRNA-resistant CD147 replacement vector was 
generated based on a previously reported CD147 expres-





RhoA biosensor was obtained from Addgene.
Western blot
Cell pellets were lysed with RIPA buffer (Beyotime, 
China) containing protease inhibitor (Roche, Switzer-
land). Blots were probed with the appropriate antibodies 
and developed using ECL kit (Pierce, US).
RNA interference
Cells were transfected with a pool of siRNAs using 
HiPerFect Transfection Reagent according to the manu-
facturer’s instruction (Qiagen). siRNA mixes target-
ing CD147 or p190-B were designed and synthesized by 
Shanghai GenePharma Co. (Shanghai, China). Silencer 
negative control siRNA (siCtrl) was used as a nega-
tive control under similar conditions. The sequence for 
siRNA targeting CD147 used in rescue experiment was 
5′-GUUCUUCGUGAGUUCCUCtt-3′.
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Quantitative real‑time PCR analysis
Total RNA was extracted using the TRIzol reagents 
(OMEGA Bio-Tek). Reverse transcription was performed 
using the PrimeScript RT reagent Kit (TaKaRa Biotech-
nology). All primers were synthesized by BGI (BGI, 
Shenzhen, China). Primer sequences were listed in Table 
X. Real-time PCR was performed using the SYBR Premix 
Ex Taq II Kit (TaKaRa Biotechnology).
In vitro wound‑healing assay
In vitro wound-healing assay was performed as described 
previously [8]. Briefly, 24 h after treatment, the cells were 
harvested and seeded in 12-well plates until confluent. A 
pipette tip was used to scratch the monolayer. The cells 
were then washed with serum-free medium. Photomi-
crographs were obtained at two time points (0 and 24 h), 
and the relative migration distance was calculated using 
the following formula: the relative migration distance 
(%) = 100 (AX−BX)/(A blank−B blank), where A is the 
width of the cell wound before incubation, and B is the 
width of the cell wound after incubation.
Fluorometric analysis of the RhoA activation
Cells were prepared as previously reported [20]. Images 
were obtained using an A1 confocal microscopy (Nikon, 
Japan). For emission ratio imaging, the filter sets were 
used as previously reported [21]. NIS-Elements software 
(Nikon, Japan) was used to analyze the images following 
previously described methods [20]. Briefly, images were 
dark-current and background-subtracted. Binary masks 
generated through intensity thresholding were applied 
to each emission channels, and the matched FRET and 
donor image sets were ratioed to depict RhoA activation 
throughout the cell. A linear pseudocolour lookup table 
was applied.
Immunofluorescence
Immunofluorescence was performed as described pre-
viously [8]. Briefly, cells were harvested and allowed to 
attach for 24  h to fibronectin-pre-coated cell culture 
dishes with glass bottoms (801002, NEST Biotechnology 
Co., LTD.). After washing twice with PBS, the cells were 
fixed in paraformaldehyde in PBS, permeabilized with 
0.1 % Triton X-100, and blocked with 1 % BSA in PBS for 
1  h. The dishes were first incubated with the indicated 
antibodies for 1 h, washed twice with PBS, and then incu-
bated with Alexa 488-phalloidin solution and the cor-
responding FITC-conjugated secondary antibodies for 
30 min in the dark. Cell nuclei were dyed with DAPI (Vec-
tor Labs). After washing, the cells were visualized using an 
A1R-A1 confocal laser microscope system (Nikon, Japan).
Statistical analysis
The results were expressed as the mean value  ±  SD of 
individual experiments. Comparisons of means were con-
ducted using student’s t test or one-way ANOVA (Graph-
Pad Prism, version 6.0). Spearman correlation analysis 
was used to assess the correlation between CD147 and 
p190-B in tissues. P values less than 0.05 were considered 
as statistically significant.
Results
CD147 promotes cell movement and inhibits RhoA 
activation
We began by determining the effects of CD147 silencing 
on HCC cells motility. The expression of CD147 in cells 
transfected with siRNAs targeting CD147 (siCD147) was 
significantly reduced compared to the cells transfected 
with control siRNA (siCtrl) (Fig.  1a). Wound-healing 
assay was used to investigate the role of CD147 in cell 
movement in HCC cells. A significant decrease was 
observed in SMMC-7721 cells transfected with siCD147 
compared to the control cells (Fig.  1b). To exclude the 
possibility of off-target effect of siRNA-mediated CD147 
interference, a siRNA-resistant CD147 replacement 
vector was generated. The expression of CD147 in cells 
cotransfected with siCD147 and the CD147 replace-
ment vector was rescued (Fig. 1a) and cell motility was 
also rescued (Fig. 1b), indicating that CD147 exerts posi-
tive regulation over hepatoma cells. RhoA, one of the 
most extensively studied members of the Rho family of 
small GTPases, is most readily recognized for its con-
tributions to actin-myosin contractility and stress fiber 
formation mainly by activating effector proteins such as 
Rho kinase, which promotes myosin-2 activation [22]. 
Thus, we determined the effects of CD147 silencing on 
RhoA activation. We found that CD147 silencing led 
to increased RhoA activation (Fig.  1c), indicating that 
CD147 may regulate cell movement via inhibiting RhoA 
activation.
CD147 promotes p190‑B expression in HCC cells
To determine the mechanism underlying the down-
regulation of RhoA activation by CD147 silencing, we 
examined the expression of p190 RhoGAPs. Strikingly, 
we found that p190-B, but not p190-A, was decreased 
in HCC cells transfected with siCD147 both at mRNA 
(Fig.  2a, b) and protein levels (Fig.  2c, d). Also, forced 
expression of CD147 in HCC cells resulted in increased 
expression of p190-B both at mRNA (Fig. 3a, c) and pro-
tein levels (Fig.  3d), indicating that CD147 promotes 
p190-B expression both at mRNA and protein levels in 
HCC cells.
Page 4 of 12Chen et al. Cancer Cell Int  (2016) 16:69 
Fig. 1 CD147 promotes cell movement and inhibits RhoA activation. a The expression of CD147 was measured by Western blot at 48 h after 
transfection with the indicated constructs. b Quantitative analysis of relative migration distance of SMMC‑7721 cells transfected with the indicated 
constructs. c Quantification of RhoA activation at 48 h after transfection. **p < 0.01, ***p < 0.001 by student’s t test. Error bars indicate the standard 
deviations (SD) from at least triplicate determinations
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p190‑B expression is positively correlated with the 
expression of CD147 in HCC tissues
To further illuminate the regulatory role of CD147 in 
p190-B expression, the expression of CD147 and p190-B 
in HCC tissues was evaluated by IHC. As shown in 
Fig.  4a–c and Table  1, most samples exhibited similar 
expression patterns of CD147 and p190-B. Spearman 
correlation analysis based on IHC score indicated a sig-
nificant positive correlation between the expression lev-
els of the two proteins (Fig. 4d). Together, these findings 
identify p190-B as a major RhoGAP regulated by CD147 
in HCC.
p190‑B promotes cell movement and inhibits RhoA 
activation
To better understand the role of p190-B in cell move-
ment, we determined the effects of p190-B silencing 
on cell movement and RhoA activation in HCC cells. 
We found that p190-B silencing resulted in decreased 
cell movement (Fig.  5a) and increased RhoA activation 
(Fig. 5b), indicating that p190-B may regulate cell move-
ment via inhibiting RhoA activation. As RhoA regulates 
cell movement via stimulating cytoskeleton rearrange-
ment, we examined whether p190-B could affect stress 
fiber distribution and focal adhesion formation. We 
found that p190-B silencing resulted in increased stress 
fiber and focal adhesion (Fig. 5c).
CD147 promotes cell movement by enhancing p190‑B 
expression
We have demonstrated that CD147 promotes cell move-
ment and p190-B expression. We next tried to investi-
gate whether p190-B-mediated RhoA deactivation was 
involved in the regulation of cell movement by CD147. 
This hypothesis predicted that reducing p190-B should 
impair the impact of CD147 overexpression on cell 
motility and RhoA deactivation. Accordingly, we trans-
fected SMMC-7721 cells with CD147-pCMV-HA, and 
then selectively depleted p190-B by a pool of siRNAs 
(Fig. 6a). Cell motility was increased in cells transfected 
with CD147-pCMV-HA together with control siRNAs. 
Strikingly, however, CD147 overexpression did not 
enhance cell motility to the same level in p190-B knock-
down cells as it did in control cells (Fig. 6b). This implies 
that p190-B contributes to the regulation of cell move-
ment by CD147.
Discussion
In this study we found that CD147 promotes p190-B 
expression both at mRNA and protein levels. p190-B 
was further identified as a RhoA GAP and was able to 
inhibit RhoA activation and to promote cell movement 
in HCC cells. Also, we demonstrated that the regula-
tion of RhoA activation and cell movement by CD147 
was mediated, at least partially, by p190-B in HCC 
(Fig.  6c), indicating that RhoA is an indirect target of 
CD147.
Members of the Rho GTPase family including RhoA 
operate as molecular switches that affect downstream 
signaling pathways and play a critical role in cytoskele-
ton dynamics and cell migration [23]. p190-B is a nega-
tive regulator of RhoA activity [16], which is consistent 
with our finding reported here. Aside from the canonical 
Rho GTPase RhoA, three isoforms have been identified. 
RhoA, RhoB and RhoC have high amino acid sequence 
homology. However, they differ in many biochemical 
characteristics and cellular functions. The specificity of 
p190B and the role of RhoB and RhoC in CD147-regu-
lated cell movement are still far from clear. Overexpres-
sion of p190-B in MCF-10A cells results in reduced actin 
stress fiber network and exhibit circumferential staining 
for actin [24] and knockdown of p190-B decreases cell 
spread and migration in Huh-7 cells [17], suggesting a 
role for p190-B in regulating the signaling pathways that 
influence cancer cell migration and invasion. In  vivo 
analysis using transgenic mice indicates that p190-B 
has pro-tumorigenic functions that enhance MMTV-
Neu induced mammary tumor formation and metasta-
sis [25]. Here, we show that siRNA-mediated silencing 
of p190-B in HCC cells causes reduced RhoA activation 
and increases formation of stress fiber and focal adhe-
sion, leading to decreased cell movement. Furthermore, 
CD147, a key regulator of HCC progression, is able to 
promote p190-B expression both at mRNA and protein 
levels and exerts positive influence on cancer cell motil-
ity mediated at least partially by p190-B. This regulatory 
relationship was further verified by immunohistochem-
istry staining of CD147 and p190-B in HCC tissues. 
Therefore, p190-B is involved in the regulation of cell 
movement by CD147 as a major GAP for RhoA in HCC 
cells.
CD147 has been reported to play important roles in 
HCC progression, including migration and invasion 
[10, 19, 26]. Of note, CD147 interacts with integrin β1, 
enhances expression and phosphorylation of FAK and 
paxillin, and subsequently leads to cytoskeletal rear-
rangement and morphological changes [27, 28]. Also, 
it is believed that CD147 plays a role in mediating epi-
thelial-mesenchymal transition (EMT) in the process of 
HCC progression, providing a slight clue to the func-
tion of CD147 in cytoskeleton rearrangement [29, 30]. 
Recently, we reported that CD147 promotes cell motility 
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Fig. 2 Silencing CD147 leads to decreased p190‑B expression. a, b Relative quantitative real‑time RT‑PCR analysis of p190 RhoGAP family in indi‑
cated cells transfected with siCD147 or siCtrl at 24 h after transfection. ***p < 0.001, ns p > 0.05 by student’s t test. c, d The expression of p190‑A or 
p190‑B in indicated cells transfected with siCD147 or siCtrl was determined by Western blot at 48 h after transfection
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Fig. 3 Overexpression of CD147 results in upregulation of p190‑B expression. a–c Relative quantitative real‑time RT‑PCR analysis of p190 RhoGAP 
family in indicated cells transfected with pCMV‑HA or CD147‑pCMV‑HA at 24 h after transfection. ***p < 0.001, **p < 0.01, ns p > 0.05 by student’s t 
test. d The expression of indicated molecules in SMMC‑7721 cells transfected with pCMV‑HA or CD147‑pCMV‑HA was determined by Western blot 
at 48 h after transfection. Error bars indicate SD from at least triplicate determinations
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by regulating Annexin A2-activated RhoA [7], enhances 
Src activity and promotes mesenchymal-type cell move-
ment by up-regulating RacGEF DOCK8 [8], is able to 
promote WAVE2-mediated lamellipodia formation 
and cell movement [9]. All these results, together with 
our data reported here, suggest that CD147 regulates 
cytoskeleton rearrangement and cell movement at mul-
tiple levels and through different mechanisms, however, 
how to coordinate these mechanisms during regulating 
cell movement still awaits further investigation and it is 
still difficult to dissect to what extent each mechanism 
Fig. 4 Immunohistochemical analysis of CD147 and p190‑B expression in the resected tumor. a–c Representative images of immunohistochemical 
staining for CD147 and p190‑B in paired HCC tissues. The scores for CD147 in patient 040081, 062474 and 080532 were grade 1, grade 2 and grade 
2, respectively. The scores for p190‑B in the indicated patients were grade 2, grade 2 and grade 1, respectively. The scale bar represents 10 μm. d The 
relationship between CD147 and p190‑B expression. **p = 0.001 by Spearman correlation
Table 1 Correlation between  CD147 and  p190-B expres-
sion in HCC tissues
Using the Spearman correlation analysis, ρ = 0.469, p = 0.001
CD147 expression p190‑B expression Total, N
– + ++
– 15 3 0 18
+ 8 12 4 24
++ 2 1 2 5
Total, N 25 16 6 47
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Fig. 5 p190‑B promotes cell movement and inhibits RhoA activation. SMMC‑7721 cells were transfected with a pool of siRNAs targeting p190‑B 
or siCtrl. a Quantitative analysis of relative migration distance by wound‑healing assay. ***p < 0.001 by student’s t test. b Quantification of RhoA 
activation in indicated cells at 48 h after transfection. *p < 0.05 by student’s t test. c Cells were stained with DAPI, rhodamine‑conjugated phalloidin 
and an antibody against paxillin and imaged by confocal microscopy. Arrows indicate focal adhesions. Error bars indicate SD from at least triplicate 
determinations
Page 10 of 12Chen et al. Cancer Cell Int  (2016) 16:69 
Fig. 6 CD147 inhibits RhoA activation through enhancing p190‑B expression. SMMC‑7721 cells were transfected with the indicated constructs. a 
The expression of CD147 and p190‑B was analyzed by Western blot. b Quantitative analysis of relative migration distance by wound‑healing assay. 
*p < 0.05, ***p < 0.001 by ANOVA. c Schematic representation of major mechanisms of CD147 in regulating cancer cell movement via promoting 
p190‑B expression. Error bars indicate SD from at least triplicate determinations
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contributes to regulation of cell movement under diverse 
circumstances. Above all, targeting CD147 could be a 
promising strategy to reduce migration and metastasis of 
tumor cells.
Conclusions
The results of this study do support the regulatory role 
of CD147 on cytoskeleton rearrangement in HCC. 
p190-B, a negative regulator of RhoA, contributes to 
the regulation of RhoA activation and cell movement 
by CD147. CD147 could be a promising target mol-
ecule for developing new anti-cancer drugs.
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